Literature DB >> 22155646

What makes a good drug target?

Isabella Gashaw1, Peter Ellinghaus, Anette Sommer, Khusru Asadullah.   

Abstract

Novel therapeutics in areas with a high unmet medical need are based on innovative drug targets. Although 'biologicals' have enlarged the space of druggable molecules, the number of appropriate drug targets is still limited. Discovering and assessing the potential therapeutic benefit of a drug target is based not only on experimental, mechanistic and pharmacological studies but also on a theoretical molecular druggability assessment, an early evaluation of potential side effects and considerations regarding opportunities for commercialization. This article defines key properties of a good drug target from the perspective of a pharmaceutical company.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Year:  2011        PMID: 22155646     DOI: 10.1016/j.drudis.2011.12.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  27 in total

Review 1.  Histone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferases.

Authors:  Jayme L Dahlin; Xiaoyue Chen; Michael A Walters; Zhiguo Zhang
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-11-03       Impact factor: 8.250

Review 2.  Mitigating risk in academic preclinical drug discovery.

Authors:  Jayme L Dahlin; James Inglese; Michael A Walters
Journal:  Nat Rev Drug Discov       Date:  2015-04       Impact factor: 84.694

3.  TREAP: A New Topological Approach to Drug Target Inference.

Authors:  Muying Wang; Lauren L Luciani; Heeju Noh; Ericka Mochan; Jason E Shoemaker
Journal:  Biophys J       Date:  2020-10-29       Impact factor: 4.033

Review 4.  RNA therapy: Are we using the right molecules?

Authors:  Ai-Ming Yu; Chao Jian; Allan H Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

5.  Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.

Authors:  Zhiqing Liu; Yi Li; Haiying Chen; Hsien-Tsung Lai; Pingyuan Wang; Shwu-Yuan Wu; Eric A Wold; Paul G Leonard; Sarah Joseph; Haitao Hu; Cheng-Ming Chiang; Allan R Brasier; Bing Tian; Jia Zhou
Journal:  J Med Chem       Date:  2022-01-04       Impact factor: 7.446

6.  In Silico, In Vitro, and Pharmacokinetic Studies of UBMC-4, a Potential Novel Compound for Treating against Trypanosoma cruzi.

Authors:  Christian Bustamante; Andrés Felipe Díez-Mejía; Natalia Arbeláez; Maurilio José Soares; Sara M Robledo; Rodrigo Ochoa; Rubén E Varela-M; Marcel Marín-Villa
Journal:  Pathogens       Date:  2022-05-24

Review 7.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

8.  Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.

Authors:  Paul N Black; Constance Ahowesso; David Montefusco; Nipun Saini; Concetta C DiRusso
Journal:  Medchemcomm       Date:  2016-02-19       Impact factor: 3.597

9.  HER2 Overexpression in Retinoblastoma: A Potential Therapeutic Target?

Authors:  David Cordeiro Sousa; Pablo Zoroquiain; Maria Eugenia Orellana; Ana Beatriz Dias; Evangelina Esposito; Miguel N Burnier
Journal:  Ocul Oncol Pathol       Date:  2017-02-23

Review 10.  From Genome to Drugs: New Approaches in Antimicrobial Discovery.

Authors:  Federico Serral; Florencia A Castello; Ezequiel J Sosa; Agustín M Pardo; Miranda Clara Palumbo; Carlos Modenutti; María Mercedes Palomino; Alberto Lazarowski; Jerónimo Auzmendi; Pablo Ivan P Ramos; Marisa F Nicolás; Adrián G Turjanski; Marcelo A Martí; Darío Fernández Do Porto
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.